세계의 원발성 담즙성 담관염 치료제 시장 보고서(2025년)

Primary biliary cholangitis (PBC) therapeutics are treatments aimed at managing and slowing the progression of primary biliary cholangitis, a chronic autoimmune liver disease that harms the bile ducts. These therapies function by improving bile flow, reducing inflammation, and preventing liver fibrosis. Their primary goal is to decrease liver inflammation, enhance bile drainage, prevent fibrosis, and delay liver failure.

The primary drug categories for PBC therapeutics include ursodeoxycholic acid, obeticholic acid, and others. Ursodeoxycholic acid is a bile acid that helps improve liver function by reducing bile accumulation and slowing liver damage, particularly in cholestatic liver conditions like PBC. These drugs operate through various mechanisms of action such as receptor agonists, receptor modulators, enzyme activators, enzyme inhibitors, and more. They are distributed through multiple channels including hospital pharmacies, retail drug stores, and online pharmacies, serving key users for both human and veterinary applications.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The primary biliary cholangitis therapeutics market research report is one of a series of new reports from The Business Research Company that provides primary biliary cholangitis therapeutics market statistics, including the primary biliary cholangitis therapeutics industry global market size, regional shares, competitors with the primary biliary cholangitis therapeutics market share, detailed primary biliary cholangitis therapeutics market segments, market trends, opportunities, and any further data you may need to thrive in the primary biliary cholangitis therapeutics industry. This primary biliary cholangitis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The primary biliary cholangitis therapeutics market size has grown rapidly in recent years. It will grow from $0.89 billion in 2024 to $1.01 billion in 2025 at a compound annual growth rate (CAGR) of 13.3%. Growth during the historic period was driven by increasing awareness of autoimmune liver diseases, expanding clinical evidence supporting liver function testing, growing investment in hepatology research, and a rising prevalence of autoimmune conditions.

The primary biliary cholangitis therapeutics market size is expected to see rapid growth in the next few years. It will grow to $1.64 billion in 2029 at a compound annual growth rate (CAGR) of 12.9%. Growth in the forecast period is expected to be driven by the increased use of second-line therapies, a growing pipeline of new therapeutics, rising adoption of combination treatments, expanded global access to diagnostics and specialty care, and enhanced patient advocacy and education efforts. Key trends anticipated include personalized treatment strategies, broader availability of second-line therapies, focus on non-invasive biomarkers, greater attention to symptom management, and the integration of real-world evidence (RWE).

The rising prevalence of liver diseases is anticipated to drive the growth of the primary biliary cholangitis therapeutics market in the coming years. Liver diseases encompass various conditions that disrupt normal liver function, often causing inflammation, scarring, or liver failure. This increase in liver disease cases is largely attributed to higher alcohol consumption, as excessive drinking damages liver cells and leads to chronic inflammation. Primary biliary cholangitis therapeutics help manage these conditions by targeting bile duct inflammation, slowing disease progression, and preserving liver function. These treatments improve patient outcomes by reducing symptoms, enhancing quality of life, and postponing the need for liver transplantation. For example, in March 2022, the US Centers for Disease Control and Prevention reported that deaths from chronic liver diseases in Texas rose to 5,079, up from 4,930 in 2021. Therefore, the growing prevalence of liver diseases is supporting the expansion of the primary biliary cholangitis therapeutics market.

Leading companies in the primary biliary cholangitis therapeutics market are focusing on developing innovative products and securing approvals for drugs like peroxisome proliferator-activated receptor (PPAR) agonists, which improve bile acid metabolism and slow disease progression. PPAR agonists activate PPAR proteins that regulate genes involved in metabolism, inflammation, and energy balance. For instance, in August 2024, Gilead Sciences Inc., a US pharmaceutical company, received accelerated approval from the U.S. Food and Drug Administration (FDA) for Livdelzi (seladelpar) to treat primary biliary cholangitis (PBC) in adults who have shown an inadequate response to ursodeoxycholic acid (UDCA) or cannot tolerate it. Livdelzi is an oral, selective PPARδ agonist that activates the PPARδ receptor to regulate genes that reduce liver inflammation, improve bile acid metabolism, and slow the progression of PBC.

In March 2024, Gilead Sciences Inc. acquired CymaBay Therapeutics Inc. for $4.3 billion. This acquisition aims to enhance Gilead's liver disease portfolio by incorporating CymaBay's investigational therapy, seladelpar, which shows promise as a treatment for primary biliary cholangitis (PBC), a rare and chronic liver condition. CymaBay Therapeutics Inc. is a US-based pharmaceutical firm specializing in developing innovative therapies for PBC.

Major players in the primary biliary cholangitis therapeutics market are F. Hoffmann-La Roche Ltd, Parvus Therapeutics, Novartis AG, Gilead Sciences Inc., Viatris Inc., Ipsen Pharma, Hanmi Pharmaceutical Co. Ltd., Intercept Pharmaceuticals, Enanta Pharmaceuticals, Mirum Pharmaceuticals, Calliditas Therapeutics AB, Dr. Falk Pharma GmbH, NGM Biopharmaceuticals Inc., Durect Corporation, COUR Pharmaceuticals, HighTide Therapeutics Inc., Pliant Therapeutics Inc., Tiziana Life Sciences, Phenex Pharmaceuticals, and Synlogic Therapeutics.

North America was the largest region in the primary biliary cholangitis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in primary biliary cholangitis therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the primary biliary cholangitis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary biliary cholangitis therapeutics market consists of sales of Livdelzi, Iqirvo, Volixibat, fibrates, immunosuppressants, and emerging biologics. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Primary Biliary Cholangitis Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on primary biliary cholangitis therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for primary biliary cholangitis therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The primary biliary cholangitis therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug: Ursodeoxycholic Acid; Obeticholic Acid; Other Drugs
• 2) By Mechanism Of Action (MOA): Receptor Agonist; Receptor Modulator; Enzyme Activator; Enzyme Inhibitor; Other Mechanisms Of Action
• 3) By Distribution Channel: Hospital Pharmacies; Drug Store And Retail Pharmacies; Online Pharmacies
• 4) By Use: Human; Veterinary
• Subsegments:
• 1) By Ursodeoxycholic Acid: Branded Ursodeoxycholic Acid; Generic Ursodeoxycholic Acid; Combination Therapies With Ursodeoxycholic Acid
• 2) By Obeticholic Acid: Monotherapy; Combination Therapy; Branded Obeticholic Acid
• 3) By Other Drugs: Fibrates; Budesonide; Immunosuppressants; Investigational Drugs Or Pipeline Candidates
• Companies Mentioned: F. Hoffmann-La Roche Ltd; Parvus Therapeutics; Novartis AG; Gilead Sciences Inc.; Viatris Inc.; Ipsen Pharma; Hanmi Pharmaceutical Co. Ltd.; Intercept Pharmaceuticals; Enanta Pharmaceuticals; Mirum Pharmaceuticals; Calliditas Therapeutics AB; Dr. Falk Pharma GmbH; NGM Biopharmaceuticals Inc.; Durect Corporation; COUR Pharmaceuticals; HighTide Therapeutics Inc.; Pliant Therapeutics Inc.; Tiziana Life Sciences; Phenex Pharmaceuticals; Synlogic Therapeutics
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Primary Biliary Cholangitis Therapeutics Market Characteristics

3. Primary Biliary Cholangitis Therapeutics Market Trends And Strategies

4. Primary Biliary Cholangitis Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Primary Biliary Cholangitis Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Primary Biliary Cholangitis Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Primary Biliary Cholangitis Therapeutics Market Growth Rate Analysis
• 5.4. Global Primary Biliary Cholangitis Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Primary Biliary Cholangitis Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Primary Biliary Cholangitis Therapeutics Total Addressable Market (TAM)

6. Primary Biliary Cholangitis Therapeutics Market Segmentation

• 6.1. Global Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ursodeoxycholic Acid
• Obeticholic Acid
• Other Drugs
• 6.2. Global Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Receptor Agonist
• Receptor Modulator
• Enzyme Activator
• Enzyme Inhibitor
• Other Mechanisms Of Action
• 6.3. Global Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Drug Store And Retail Pharmacies
• Online Pharmacies
• 6.4. Global Primary Biliary Cholangitis Therapeutics Market, Segmentation By Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Human
• Veterinary
• 6.5. Global Primary Biliary Cholangitis Therapeutics Market, Sub-Segmentation Of Ursodeoxycholic Acid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Branded Ursodeoxycholic Acid
• Generic Ursodeoxycholic Acid
• Combination Therapies With Ursodeoxycholic Acid
• 6.6. Global Primary Biliary Cholangitis Therapeutics Market, Sub-Segmentation Of Obeticholic Acid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monotherapy
• Combination Therapy
• Branded Obeticholic Acid
• 6.7. Global Primary Biliary Cholangitis Therapeutics Market, Sub-Segmentation Of Other Drugs, By type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fibrates
• Budesonide
• Immunosuppressants
• Investigational Drugs Or Pipeline Candidates

7. Primary Biliary Cholangitis Therapeutics Market Regional And Country Analysis

• 7.1. Global Primary Biliary Cholangitis Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Primary Biliary Cholangitis Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Primary Biliary Cholangitis Therapeutics Market

• 8.1. Asia-Pacific Primary Biliary Cholangitis Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Primary Biliary Cholangitis Therapeutics Market

• 9.1. China Primary Biliary Cholangitis Therapeutics Market Overview
• 9.2. China Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Primary Biliary Cholangitis Therapeutics Market

• 10.1. India Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Primary Biliary Cholangitis Therapeutics Market

• 11.1. Japan Primary Biliary Cholangitis Therapeutics Market Overview
• 11.2. Japan Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Primary Biliary Cholangitis Therapeutics Market

• 12.1. Australia Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Primary Biliary Cholangitis Therapeutics Market

• 13.1. Indonesia Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Primary Biliary Cholangitis Therapeutics Market

• 14.1. South Korea Primary Biliary Cholangitis Therapeutics Market Overview
• 14.2. South Korea Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Primary Biliary Cholangitis Therapeutics Market

• 15.1. Western Europe Primary Biliary Cholangitis Therapeutics Market Overview
• 15.2. Western Europe Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Primary Biliary Cholangitis Therapeutics Market

• 16.1. UK Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Primary Biliary Cholangitis Therapeutics Market

• 17.1. Germany Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Primary Biliary Cholangitis Therapeutics Market

• 18.1. France Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Primary Biliary Cholangitis Therapeutics Market

• 19.1. Italy Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Primary Biliary Cholangitis Therapeutics Market

• 20.1. Spain Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Primary Biliary Cholangitis Therapeutics Market

• 21.1. Eastern Europe Primary Biliary Cholangitis Therapeutics Market Overview
• 21.2. Eastern Europe Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Primary Biliary Cholangitis Therapeutics Market

• 22.1. Russia Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Primary Biliary Cholangitis Therapeutics Market

• 23.1. North America Primary Biliary Cholangitis Therapeutics Market Overview
• 23.2. North America Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Primary Biliary Cholangitis Therapeutics Market

• 24.1. USA Primary Biliary Cholangitis Therapeutics Market Overview
• 24.2. USA Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Primary Biliary Cholangitis Therapeutics Market

• 25.1. Canada Primary Biliary Cholangitis Therapeutics Market Overview
• 25.2. Canada Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Primary Biliary Cholangitis Therapeutics Market

• 26.1. South America Primary Biliary Cholangitis Therapeutics Market Overview
• 26.2. South America Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Primary Biliary Cholangitis Therapeutics Market

• 27.1. Brazil Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Primary Biliary Cholangitis Therapeutics Market

• 28.1. Middle East Primary Biliary Cholangitis Therapeutics Market Overview
• 28.2. Middle East Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Primary Biliary Cholangitis Therapeutics Market

• 29.1. Africa Primary Biliary Cholangitis Therapeutics Market Overview
• 29.2. Africa Primary Biliary Cholangitis Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Primary Biliary Cholangitis Therapeutics Market, Segmentation By Mechanism Of Action (MOA), Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Primary Biliary Cholangitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Primary Biliary Cholangitis Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Primary Biliary Cholangitis Therapeutics Market Competitive Landscape
• 30.2. Primary Biliary Cholangitis Therapeutics Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Parvus Therapeutics Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Primary Biliary Cholangitis Therapeutics Market Other Major And Innovative Companies

• 31.1. Ipsen Pharma
• 31.2. Hanmi Pharmaceutical Co. Ltd.
• 31.3. Intercept Pharmaceuticals
• 31.4. Enanta Pharmaceuticals
• 31.5. Mirum Pharmaceuticals
• 31.6. Calliditas Therapeutics AB
• 31.7. Dr. Falk Pharma GmbH
• 31.8. NGM Biopharmaceuticals Inc.
• 31.9. Durect Corporation
• 31.10. COUR Pharmaceuticals
• 31.11. HighTide Therapeutics Inc.
• 31.12. Pliant Therapeutics Inc.
• 31.13. Tiziana Life Sciences
• 31.14. Phenex Pharmaceuticals
• 31.15. Synlogic Therapeutics

32. Global Primary Biliary Cholangitis Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Primary Biliary Cholangitis Therapeutics Market

34. Recent Developments In The Primary Biliary Cholangitis Therapeutics Market

35. Primary Biliary Cholangitis Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Primary Biliary Cholangitis Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Primary Biliary Cholangitis Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Primary Biliary Cholangitis Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer